Group 1 - The company reported a preliminary financial data for the year 2025, which is subject to final audit and may differ from the final report [1][4] - The company achieved an operating revenue of 4.22 billion yuan, a decrease of 4.87% year-on-year [3] - The net profit attributable to shareholders of the listed company was 906 million yuan, reflecting a year-on-year increase of 14.96% [3] Group 2 - The company is focusing on brand building and strengthening its core business through "big single products and strong categories" [3] - Marketing strategies have been enriched, with an emphasis on return on investment and optimizing cost structures [3] - The company is implementing lean manufacturing to reduce costs and improve efficiency, contributing to the enhancement of profitability [3]
华润江中药业股份有限公司 2025年年度业绩快报公告